Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

NCT05546580 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory

Interventions

DRUG: Iadademstat
DRUG: Gilteritinib Oral Tablet

Sponsor

Oryzon Genomics S.A.